|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Amylin Pharmaceuticals Inc., of San Diego, said a dose-titration study of its diabetes drug candidate Symlin (pramlintide acetate) met prospectively defined parameters for its non-inferiority objective. In addition to reductions in HbA1c consistent with the non-inferiority objective in the 296-patient study, Symlin-treated subjects used 12 percent less insulin overall compared to control. Symlin also was associated with a significant reduction in post-meal blood glucose concentrations compared to the group using insulin alone, and the effect was sustained over the entire seven months of the study. At the end, Symlin-treated subjects experienced a reduction in weight, ...
Related newspaper, magazine, and journal articles:
|
|
Article: HEAD, NECK TUMORS' GROWTH HALTED ONYX'S VIRAL ANTICANCER DRUG ...
BIOWORLD Today;
November 24, 1998 ;
700+ words
... ... The company said efficacy has been seen in mouse tumor models. Results of the Phase II study were presented Saturday in San Diego at the Seventh International Conference on Gene Therapy of Cancer. Onyx's stock (NASDAQ:ONXX), which was as low as ...
|
|